liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren’s Syndrome
Institut Gustave Roussy (IGR), Villejuif, France .
Université Paris-Sud, Le Kremlin Bicêtre, France.
Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France. .
Institut Gustave Roussy (IGR), Villejuif, France .
Show others and affiliations
2013 (English)In: Science Translational Medicine, ISSN 1946-6234, Vol. 5, no 195Article in journal (Refereed) Published
Abstract [en]

Primary Sjögrens syndrome (pSS) is a chronic autoimmune disease characterized by a lymphocytic exocrinopathy. However, patients often have evidence of systemic autoimmunity, and they are at markedly increased risk for the development of non-Hodgkins lymphoma. Similar to other autoimmune disorders, a strong interferon (IFN) signature is present among subsets of pSS patients, although the precise etiology remains uncertain. NCR3/NKp30 is a natural killer (NK)-specific activating receptor regulating the cross talk between NK and dendritic cells and type II IFN secretion. We performed a case-control study of genetic polymorphisms of the NCR3/NKp30 gene and found that rs11575837 (Gandgt;A) residing in the promoter was associated with reduced gene transcription and function as well as protection to pSS. We also demonstrated that circulating levels of NCR3/NKp30 were significantly increased among pSS patients compared with controls and correlated with higher NCR3/NKp30 but not CD16-dependent IFN-gamma secretion by NK cells. Excess accumulation of NK cells in minor salivary glands correlated with the severity of the exocrinopathy. B7H6, the ligand of NKp30, was expressed by salivary epithelial cells. These findings suggest that NK cells may promote an NKp30-dependent inflammatory state in salivary glands and that blockade of the B7H6/NKp30 axis could be clinically relevant in pSS.

Place, publisher, year, edition, pages
American Association for the Advancement of Science , 2013. Vol. 5, no 195
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-96986DOI: 10.1126/scitranslmed.3005727ISI: 000322233400008PubMedID: 23884468OAI: diva2:644946

Funding Agencies|French Ministry of Health|PHRC 2006-AOM06133PHRC 2010-AOM10188|Direction de la Recherche Clinique, Assistance Publique-Hopitaux de Paris||French Ministry of Research|ANR- 2010-BLAN-1133 01|LIGUE Francaise contre le Cancer (Label) INCA||Fondation de France||INFLACARE FP7||SIRIC Socrates||LABEX immuno-oncology||Fondation pour la Recherche Medicale||Swedish Rheumatism Association||Swedish Research Council||Broegelmann Foundation||Strategic Research Program at Helse Bergen||NIH|P50 AR06080405R01 DE0152235U19 AI0827141R01 DE018209-025R01 DE0182093P20 RR0201435P01 AI083194-03|American College of Rheumatology Research and Education Foundation/Abbott Healthy Professional Graduate Student Preceptorship Award||Oklahoma Medical Research Foundation||Sjogrens Syndrome Foundation|4434|Phileona Foundation||

Available from: 2013-09-02 Created: 2013-09-02 Last updated: 2014-03-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Eriksson, Per
By organisation
RheumatologyFaculty of Health SciencesDepartment of Rheumatology
In the same journal
Science Translational Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 79 hits
ReferencesLink to record
Permanent link

Direct link